5327-31-1

Basic information

• Product Name: Nicotinic acid, 2-amino-, hydrazide
• Synonyms: Nicotinic acid, 2-amino-, hydrazide;2-Aminonicotinohydrazide;2-aminopyridine-3-carbohydrazide;2-azanylpyridine-3-carbohydrazide;2-AMinonicotinic acid hydrazide
• CAS NO: 5327-31-1
• Molecular Formula: C₆H₈N₄O
• Molecular Weight: 152.16
• Product Categories: pharmacetical
• Mol File: 5327-31-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.352g/cm³
• Refractive Index: 1.651
• CAS DataBase Reference: Nicotinic acid, 2-amino-, hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Nicotinic acid, 2-amino-, hydrazide(5327-31-1)
• EPA Substance Registry System: Nicotinic acid, 2-amino-, hydrazide(5327-31-1)

Safety Data

• Hazardous Substances Data: 5327-31-1(Hazardous Substances Data)

Usage

General Description

Nicotinic acid, 2-amino-, hydrazide, also known as isoniazid, is an organic compound that is commonly used as an antibiotic medication to treat tuberculosis. It works by inhibiting the synthesis of mycolic acids, which are crucial components of the cell walls of tuberculosis bacteria. Additionally, it is used as a preventive treatment for those at risk of developing tuberculosis, such as close contacts of people with active tuberculosis. Isoniazid is often combined with other antibiotics for the treatment of tuberculosis, such as rifampin, pyrazinamide, and ethambutol. Despite its effectiveness, isoniazid may have side effects such as liver damage, peripheral neuropathy, and allergic reactions, and may interact with other medications.

InChI:InChI=1/C6H8N4O/c7-5-4(6(11)10-8)2-1-3-9-5/h1-3H,8H2,(H2,7,9)(H,10,11)

Upstream product

• 14667-47-1 methyl 2-aminonicotinate 
• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 

Downstream Products

• 7521-41-7 2-Aminonicotinaldehyde 
• 64189-05-5 2-Amino-3-(1',3','-oxadiazolyl-5')pyridin 
• 102007-64-7 2-benzylidenamino-nicotinic acid benzylidenehydrazide 

Relevant articles and documents

Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis

Glycine-N-methyl transferase (GNMT) downregulation results in spontaneous hepatocellular carcinoma (HCC). Overexpression of GNMT inhibits the proliferation of liver cancer cell lines and prevents carcinogen-induced HCC, suggesting that GNMT induction is a potential approach for anti-HCC therapy. Herein, we used Huh7 GNMT promoter-driven screening to identify a GNMT inducer. Compound K78 was identified and validated for its induction of GNMT and inhibition of Huh7 cell growth. Subsequently, we employed structure-activity relationship analysis and found a potent GNMT inducer, K117. K117 inhibited Huh7 cell growth in vitro and xenograft in vivo. Oral administration of a dosage of K117 at 10 mpk (milligrams per kilogram) can inhibit Huh7 xenograft in a manner equivalent to the effect of sorafenib at a dosage of 25 mpk. A mechanistic study revealed that K117 is an MYC inhibitor. Ectopic expression of MYC using CMV promoter blocked K117-mediated MYC inhibition and GNMT induction. Overall, K117 is a potential lead compound for HCC- and MYC-dependent cancers.